Advertisement

Cancer Immunology, Immunotherapy

, Volume 45, Issue 3–4, pp 131–136 | Cite as

Tumor-specific T-bodies: towards clinical application

  • Zelig Eshhar
ORIGINAL ARTICLE

Abstract

 Unlike antibodies, T cells are well suited to penetrate and destroy solid tumors. The T-body approach combines antibody recognition and T cells effector function. It is based on T cells expressing chimeric receptors composed of antibody-derived Fv or scFv as their extracellular recognition elements joined to lymphocyte triggering molecules. This receptors can redirect the specificity of T cells in an MHC independent manner. Upon encountering their target cells, T-bodies are able to undergo specific stimulation for interleukin/cytokine production, and kill hapten-modified or tumor cells in model systems both in vitro and in vivo. T cells expressing chimeric receptors made of antitumor antibodies are able to discriminate between a tumor and normal cell with negligible bystander cytotoxicity. Further studies should be carried out to evaluate and optimize the persistence, homing patterns and reactivation potential of T-bodies in the body.

Key words: Tumor-specific T-bodies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • Zelig Eshhar
    • 1
  1. 1.The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: lieshhar@weizmann.weizmann.ac.ilIL

Personalised recommendations